Status:
TERMINATED
STerOids in COVID-19 Study
Lead Sponsor:
University of Oxford
Conditions:
Coronavirus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
At the time of writing (3/4/2020), close to a million people have been infected by the SARS-CoV-2 coronavirus around the world. The severe clinical condition that leads to deaths is now called CoVID-1...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the trial
- Male or Female, aged 18 years or above
- New onset of symptoms suggestive of COVID-19 e.g. new onset cough and/or fever, and/or loss of smell or taste within 7 or fewer days of participant being seen at visit 1
- In the Investigator's opinion, is able and willing to comply with all trial requirements
Exclusion
- A known allergy to investigational medicine product (IMP) (budesonide)
- Any known contraindication to any of the IMPs (budesonide)
- Patient currently prescribed inhaled or systemic corticosteroids
- Recent use, within the previous 7 days of inhaled or systemic corticosteroids
- Patient needs hospitalisation at time of study consent
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
Key Trial Info
Start Date :
July 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 12 2021
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT04416399
Start Date
July 16 2020
End Date
January 12 2021
Last Update
February 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford Respiratory Trials Unit
Oxford, Oxfordshire, United Kingdom, OX3 7LE